Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
Status:
Completed
Trial end date:
2023-04-20
Target enrollment:
Participant gender:
Summary
The aim of study is impact of additional treatment with new antidiabetic drugs (semaglutide
or empagliflozine) compared to control group in T1DM patients - impact on endothelial
function measured by FMD and FPF, arterial stiffness - measured by PWV, inflammatory
biomarkers, markers of oxidative stress and endothelial progenitor cells (CD 34+/VDRL2, CD
133+/VDRL2) and correlation with glucovariability or time in range, measured with CGM system.